Report Detail

Pharma & Healthcare Asia-Pacific Opioid Induced Constipation (OIC) Drugs Market Report 2018

  • RnM1774931
  • |
  • 21 March, 2018
  • |
  • Global
  • |
  • 115 Pages
  • |
  • QYResearch
  • |
  • Pharma & Healthcare

In this report, the Asia-Pacific Opioid Induced Constipation (OIC) Drugs market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025.

Geographically, this report split Asia-Pacific into several key Regions, with sales (K Pcs), revenue (Million USD), market share and growth rate of Opioid Induced Constipation (OIC) Drugs for these regions, from 2013 to 2025 (forecast), including
China
Japan
South Korea
Taiwan
India
Southeast Asia
Australia

Asia-Pacific Opioid Induced Constipation (OIC) Drugs market competition by top manufacturers/players, with Opioid Induced Constipation (OIC) Drugs sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
Ironwood Pharmaceuticals Inc
Daiichi Sankyo Co Ltd
Pfizer
Progenics Pharmaceuticals Inc
Shionogi & Co., Ltd
Allergan Plc
Nektar Therapeutics
Purdue Pharma
S.L.A. Pharma AG
Mundipharma International Limited
Ono Pharmaceutical Co., Ltd
Takeda Pharmaceutical Company Limited
Theravance Biopharma Inc
Valeant Pharmaceuticals International
Cosmo Pharmaceuticals SA
Daewoong Pharmaceutical
C.B. Fleet Company
Sucampo Pharmaceuticals

On the basis of product, this report displays the sales volum, revenue, product price, market share and growth rate of each type, primarily split into
By Drug Type
Lubiprostone
Methyl Naltrexone Bromide
Naldemedine
Alvimopan
Other
By Prescription Type
Generic and Branded Prescribed Drugs
Over The Counter Drugs

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

If you have any special requirements, please let us know and we will offer you the report as you want.


Table of Contents

    Asia-Pacific Opioid Induced Constipation (OIC) Drugs Market Report 2018

      1 Opioid Induced Constipation (OIC) Drugs Overview

      • 1.1 Product Overview and Scope of Opioid Induced Constipation (OIC) Drugs
      • 1.2 Classification of Opioid Induced Constipation (OIC) Drugs by Product Category
        • 1.2.1 Asia-Pacific Opioid Induced Constipation (OIC) Drugs Market Size (Sales) Comparison by Types (2013-2025)
        • 1.2.2 Asia-Pacific Opioid Induced Constipation (OIC) Drugs Market Size (Sales) Market Share by Type (Product Category) in 2017
        • 1.2.3 Lubiprostone
        • 1.2.4 Methyl Naltrexone Bromide
        • 1.2.5 Naldemedine
        • 1.2.6 Alvimopan
        • 1.2.7 Other
      • 1.3 Asia-Pacific Opioid Induced Constipation (OIC) Drugs Market by Application/End Users
        • 1.3.1 Asia-Pacific Opioid Induced Constipation (OIC) Drugs Sales (Volume) and Market Share Comparison by Applications (2013-2025)
        • 1.3.2 Hospital Pharmacies
        • 1.3.3 Retail Pharmacies
        • 1.3.4 Online Pharmacies
      • 1.4 Asia-Pacific Opioid Induced Constipation (OIC) Drugs Market by Region
        • 1.4.1 Asia-Pacific Opioid Induced Constipation (OIC) Drugs Market Size (Value) Comparison by Region (2013-2025)
        • 1.4.2 China Status and Prospect (2013-2025)
        • 1.4.3 Japan Status and Prospect (2013-2025)
        • 1.4.4 South Korea Status and Prospect (2013-2025)
        • 1.4.5 Taiwan Status and Prospect (2013-2025)
        • 1.4.6 India Status and Prospect (2013-2025)
        • 1.4.7 Southeast Asia Status and Prospect (2013-2025)
        • 1.4.8 Australia Status and Prospect (2013-2025)
      • 1.5 Asia-Pacific Market Size (Value and Volume) of Opioid Induced Constipation (OIC) Drugs (2013-2025)
        • 1.5.1 Asia-Pacific Opioid Induced Constipation (OIC) Drugs Sales and Growth Rate (2013-2025)
        • 1.5.2 Asia-Pacific Opioid Induced Constipation (OIC) Drugs Revenue and Growth Rate (2013-2025)

      2 Asia-Pacific Opioid Induced Constipation (OIC) Drugs Competition by Players/Suppliers, Region, Type and Application

      • 2.1 Asia-Pacific Opioid Induced Constipation (OIC) Drugs Market Competition by Players/Suppliers
        • 2.1.1 Asia-Pacific Opioid Induced Constipation (OIC) Drugs Sales Volume and Market Share of Key Players/Suppliers (2013-2018)
        • 2.1.2 Asia-Pacific Opioid Induced Constipation (OIC) Drugs Revenue and Share by Players/Suppliers (2013-2018)
      • 2.2 Asia-Pacific Opioid Induced Constipation (OIC) Drugs (Volume and Value) by Type
        • 2.2.1 Asia-Pacific Opioid Induced Constipation (OIC) Drugs Sales and Market Share by Type (2013-2018)
        • 2.2.2 Asia-Pacific Opioid Induced Constipation (OIC) Drugs Revenue and Market Share by Type (2013-2018)
      • 2.3 Asia-Pacific Opioid Induced Constipation (OIC) Drugs (Volume) by Application
      • 2.4 Asia-Pacific Opioid Induced Constipation (OIC) Drugs (Volume and Value) by Region
        • 2.4.1 Asia-Pacific Opioid Induced Constipation (OIC) Drugs Sales and Market Share by Region (2013-2018)
        • 2.4.2 Asia-Pacific Opioid Induced Constipation (OIC) Drugs Revenue and Market Share by Region (2013-2018)

      3 China Opioid Induced Constipation (OIC) Drugs (Volume, Value and Sales Price)

      • 3.1 China Opioid Induced Constipation (OIC) Drugs Sales and Value (2013-2018)
        • 3.1.1 China Opioid Induced Constipation (OIC) Drugs Sales Volume and Growth Rate (2013-2018)
        • 3.1.2 China Opioid Induced Constipation (OIC) Drugs Revenue and Growth Rate (2013-2018)
        • 3.1.3 China Opioid Induced Constipation (OIC) Drugs Sales Price Trend (2013-2018)
      • 3.2 China Opioid Induced Constipation (OIC) Drugs Sales Volume and Market Share by Type
      • 3.3 China Opioid Induced Constipation (OIC) Drugs Sales Volume and Market Share by Application

      4 Japan Opioid Induced Constipation (OIC) Drugs (Volume, Value and Sales Price)

      • 4.1 Japan Opioid Induced Constipation (OIC) Drugs Sales and Value (2013-2018)
        • 4.1.1 Japan Opioid Induced Constipation (OIC) Drugs Sales Volume and Growth Rate (2013-2018)
        • 4.1.2 Japan Opioid Induced Constipation (OIC) Drugs Revenue and Growth Rate (2013-2018)
        • 4.1.3 Japan Opioid Induced Constipation (OIC) Drugs Sales Price Trend (2013-2018)
      • 4.2 Japan Opioid Induced Constipation (OIC) Drugs Sales Volume and Market Share by Type
      • 4.3 Japan Opioid Induced Constipation (OIC) Drugs Sales Volume and Market Share by Application

      5 South Korea Opioid Induced Constipation (OIC) Drugs (Volume, Value and Sales Price)

      • 5.1 South Korea Opioid Induced Constipation (OIC) Drugs Sales and Value (2013-2018)
        • 5.1.1 South Korea Opioid Induced Constipation (OIC) Drugs Sales Volume and Growth Rate (2013-2018)
        • 5.1.2 South Korea Opioid Induced Constipation (OIC) Drugs Revenue and Growth Rate (2013-2018)
        • 5.1.3 South Korea Opioid Induced Constipation (OIC) Drugs Sales Price Trend (2013-2018)
      • 5.2 South Korea Opioid Induced Constipation (OIC) Drugs Sales Volume and Market Share by Type
      • 5.3 South Korea Opioid Induced Constipation (OIC) Drugs Sales Volume and Market Share by Application

      6 Taiwan Opioid Induced Constipation (OIC) Drugs (Volume, Value and Sales Price)

      • 6.1 Taiwan Opioid Induced Constipation (OIC) Drugs Sales and Value (2013-2018)
        • 6.1.1 Taiwan Opioid Induced Constipation (OIC) Drugs Sales Volume and Growth Rate (2013-2018)
        • 6.1.2 Taiwan Opioid Induced Constipation (OIC) Drugs Revenue and Growth Rate (2013-2018)
        • 6.1.3 Taiwan Opioid Induced Constipation (OIC) Drugs Sales Price Trend (2013-2018)
      • 6.2 Taiwan Opioid Induced Constipation (OIC) Drugs Sales Volume and Market Share by Type
      • 6.3 Taiwan Opioid Induced Constipation (OIC) Drugs Sales Volume and Market Share by Application

      7 India Opioid Induced Constipation (OIC) Drugs (Volume, Value and Sales Price)

      • 7.1 India Opioid Induced Constipation (OIC) Drugs Sales and Value (2013-2018)
        • 7.1.1 India Opioid Induced Constipation (OIC) Drugs Sales Volume and Growth Rate (2013-2018)
        • 7.1.2 India Opioid Induced Constipation (OIC) Drugs Revenue and Growth Rate (2013-2018)
        • 7.1.3 India Opioid Induced Constipation (OIC) Drugs Sales Price Trend (2013-2018)
      • 7.2 India Opioid Induced Constipation (OIC) Drugs Sales Volume and Market Share by Type
      • 7.3 India Opioid Induced Constipation (OIC) Drugs Sales Volume and Market Share by Application

      8 Southeast Asia Opioid Induced Constipation (OIC) Drugs (Volume, Value and Sales Price)

      • 8.1 Southeast Asia Opioid Induced Constipation (OIC) Drugs Sales and Value (2013-2018)
        • 8.1.1 Southeast Asia Opioid Induced Constipation (OIC) Drugs Sales Volume and Growth Rate (2013-2018)
        • 8.1.2 Southeast Asia Opioid Induced Constipation (OIC) Drugs Revenue and Growth Rate (2013-2018)
        • 8.1.3 Southeast Asia Opioid Induced Constipation (OIC) Drugs Sales Price Trend (2013-2018)
      • 8.2 Southeast Asia Opioid Induced Constipation (OIC) Drugs Sales Volume and Market Share by Type
      • 8.3 Southeast Asia Opioid Induced Constipation (OIC) Drugs Sales Volume and Market Share by Application

      9 Australia Opioid Induced Constipation (OIC) Drugs (Volume, Value and Sales Price)

      • 9.1 Australia Opioid Induced Constipation (OIC) Drugs Sales and Value (2013-2018)
        • 9.1.1 Australia Opioid Induced Constipation (OIC) Drugs Sales Volume and Growth Rate (2013-2018)
        • 9.1.2 Australia Opioid Induced Constipation (OIC) Drugs Revenue and Growth Rate (2013-2018)
        • 9.1.3 Australia Opioid Induced Constipation (OIC) Drugs Sales Price Trend (2013-2018)
      • 9.2 Australia Opioid Induced Constipation (OIC) Drugs Sales Volume and Market Share by Type
      • 9.3 Australia Opioid Induced Constipation (OIC) Drugs Sales Volume and Market Share by Application

      10 Asia-Pacific Opioid Induced Constipation (OIC) Drugs Players/Suppliers Profiles and Sales Data

      • 10.1 Ironwood Pharmaceuticals Inc
        • 10.1.1 Company Basic Information, Manufacturing Base and Competitors
        • 10.1.2 Opioid Induced Constipation (OIC) Drugs Product Category, Application and Specification
          • 10.1.2.1 Product A
          • 10.1.2.2 Product B
        • 10.1.3 Ironwood Pharmaceuticals Inc Opioid Induced Constipation (OIC) Drugs Sales, Revenue, Price and Gross Margin (2013-2018)
        • 10.1.4 Main Business/Business Overview
      • 10.2 Daiichi Sankyo Co Ltd
        • 10.2.1 Company Basic Information, Manufacturing Base and Competitors
        • 10.2.2 Opioid Induced Constipation (OIC) Drugs Product Category, Application and Specification
          • 10.2.2.1 Product A
          • 10.2.2.2 Product B
        • 10.2.3 Daiichi Sankyo Co Ltd Opioid Induced Constipation (OIC) Drugs Sales, Revenue, Price and Gross Margin (2013-2018)
        • 10.2.4 Main Business/Business Overview
      • 10.3 Pfizer
        • 10.3.1 Company Basic Information, Manufacturing Base and Competitors
        • 10.3.2 Opioid Induced Constipation (OIC) Drugs Product Category, Application and Specification
          • 10.3.2.1 Product A
          • 10.3.2.2 Product B
        • 10.3.3 Pfizer Opioid Induced Constipation (OIC) Drugs Sales, Revenue, Price and Gross Margin (2013-2018)
        • 10.3.4 Main Business/Business Overview
      • 10.4 Progenics Pharmaceuticals Inc
        • 10.4.1 Company Basic Information, Manufacturing Base and Competitors
        • 10.4.2 Opioid Induced Constipation (OIC) Drugs Product Category, Application and Specification
          • 10.4.2.1 Product A
          • 10.4.2.2 Product B
        • 10.4.3 Progenics Pharmaceuticals Inc Opioid Induced Constipation (OIC) Drugs Sales, Revenue, Price and Gross Margin (2013-2018)
        • 10.4.4 Main Business/Business Overview
      • 10.5 Shionogi & Co., Ltd
        • 10.5.1 Company Basic Information, Manufacturing Base and Competitors
        • 10.5.2 Opioid Induced Constipation (OIC) Drugs Product Category, Application and Specification
          • 10.5.2.1 Product A
          • 10.5.2.2 Product B
        • 10.5.3 Shionogi & Co., Ltd Opioid Induced Constipation (OIC) Drugs Sales, Revenue, Price and Gross Margin (2013-2018)
        • 10.5.4 Main Business/Business Overview
      • 10.6 Allergan Plc
        • 10.6.1 Company Basic Information, Manufacturing Base and Competitors
        • 10.6.2 Opioid Induced Constipation (OIC) Drugs Product Category, Application and Specification
          • 10.6.2.1 Product A
          • 10.6.2.2 Product B
        • 10.6.3 Allergan Plc Opioid Induced Constipation (OIC) Drugs Sales, Revenue, Price and Gross Margin (2013-2018)
        • 10.6.4 Main Business/Business Overview
      • 10.7 Nektar Therapeutics
        • 10.7.1 Company Basic Information, Manufacturing Base and Competitors
        • 10.7.2 Opioid Induced Constipation (OIC) Drugs Product Category, Application and Specification
          • 10.7.2.1 Product A
          • 10.7.2.2 Product B
        • 10.7.3 Nektar Therapeutics Opioid Induced Constipation (OIC) Drugs Sales, Revenue, Price and Gross Margin (2013-2018)
        • 10.7.4 Main Business/Business Overview
      • 10.8 Purdue Pharma
        • 10.8.1 Company Basic Information, Manufacturing Base and Competitors
        • 10.8.2 Opioid Induced Constipation (OIC) Drugs Product Category, Application and Specification
          • 10.8.2.1 Product A
          • 10.8.2.2 Product B
        • 10.8.3 Purdue Pharma Opioid Induced Constipation (OIC) Drugs Sales, Revenue, Price and Gross Margin (2013-2018)
        • 10.8.4 Main Business/Business Overview
      • 10.9 S.L.A. Pharma AG
        • 10.9.1 Company Basic Information, Manufacturing Base and Competitors
        • 10.9.2 Opioid Induced Constipation (OIC) Drugs Product Category, Application and Specification
          • 10.9.2.1 Product A
          • 10.9.2.2 Product B
        • 10.9.3 S.L.A. Pharma AG Opioid Induced Constipation (OIC) Drugs Sales, Revenue, Price and Gross Margin (2013-2018)
        • 10.9.4 Main Business/Business Overview
      • 10.10 Mundipharma International Limited
        • 10.10.1 Company Basic Information, Manufacturing Base and Competitors
        • 10.10.2 Opioid Induced Constipation (OIC) Drugs Product Category, Application and Specification
          • 10.10.2.1 Product A
          • 10.10.2.2 Product B
        • 10.10.3 Mundipharma International Limited Opioid Induced Constipation (OIC) Drugs Sales, Revenue, Price and Gross Margin (2013-2018)
        • 10.10.4 Main Business/Business Overview
      • 10.11 Ono Pharmaceutical Co., Ltd
      • 10.12 Takeda Pharmaceutical Company Limited
      • 10.13 Theravance Biopharma Inc
      • 10.14 Valeant Pharmaceuticals International
      • 10.15 Cosmo Pharmaceuticals SA
      • 10.16 Daewoong Pharmaceutical
      • 10.17 C.B. Fleet Company
      • 10.18 Sucampo Pharmaceuticals

      11 Opioid Induced Constipation (OIC) Drugs Manufacturing Cost Analysis

      • 11.1 Opioid Induced Constipation (OIC) Drugs Key Raw Materials Analysis
        • 11.1.1 Key Raw Materials
        • 11.1.2 Price Trend of Key Raw Materials
        • 11.1.3 Key Suppliers of Raw Materials
        • 11.1.4 Market Concentration Rate of Raw Materials
      • 11.2 Proportion of Manufacturing Cost Structure
        • 11.2.1 Raw Materials
        • 11.2.2 Labor Cost
        • 11.2.3 Manufacturing Expenses
      • 11.3 Manufacturing Process Analysis of Opioid Induced Constipation (OIC) Drugs

      12 Industrial Chain, Sourcing Strategy and Downstream Buyers

      • 12.1 Opioid Induced Constipation (OIC) Drugs Industrial Chain Analysis
      • 12.2 Upstream Raw Materials Sourcing
      • 12.3 Raw Materials Sources of Opioid Induced Constipation (OIC) Drugs Major Manufacturers in 2017
      • 12.4 Downstream Buyers

      13 Marketing Strategy Analysis, Distributors/Traders

      • 13.1 Marketing Channel
        • 13.1.1 Direct Marketing
        • 13.1.2 Indirect Marketing
        • 13.1.3 Marketing Channel Development Trend
      • 13.2 Market Positioning
        • 13.2.1 Pricing Strategy
        • 13.2.2 Brand Strategy
        • 13.2.3 Target Client
      • 13.3 Distributors/Traders List

      14 Market Effect Factors Analysis

      • 14.1 Technology Progress/Risk
        • 14.1.1 Substitutes Threat
        • 14.1.2 Technology Progress in Related Industry
      • 14.2 Consumer Needs/Customer Preference Change
      • 14.3 Economic/Political Environmental Change

      15 Asia-Pacific Opioid Induced Constipation (OIC) Drugs Market Forecast (2018-2025)

      • 15.1 Asia-Pacific Opioid Induced Constipation (OIC) Drugs Sales Volume, Revenue and Price Forecast (2018-2025)
        • 15.1.1 Asia-Pacific Opioid Induced Constipation (OIC) Drugs Sales Volume and Growth Rate Forecast (2018-2025)
        • 15.1.2 Asia-Pacific Opioid Induced Constipation (OIC) Drugs Revenue and Growth Rate Forecast (2018-2025)
        • 15.1.3 Asia-Pacific Opioid Induced Constipation (OIC) Drugs Price and Trend Forecast (2018-2025)
      • 15.2 Asia-Pacific Opioid Induced Constipation (OIC) Drugs Sales Volume, Revenue and Growth Rate Forecast by Region (2018-2025)
        • 15.2.1 Asia-Pacific Opioid Induced Constipation (OIC) Drugs Sales Volume and Growth Rate Forecast by Region (2018-2025)
        • 15.2.2 Asia-Pacific Opioid Induced Constipation (OIC) Drugs Revenue and Growth Rate Forecast by Region (2018-2025)
        • 15.2.3 China Opioid Induced Constipation (OIC) Drugs Sales, Revenue and Growth Rate Forecast (2018-2025)
        • 15.2.4 Japan Opioid Induced Constipation (OIC) Drugs Sales, Revenue and Growth Rate Forecast (2018-2025)
        • 15.2.5 South Korea Opioid Induced Constipation (OIC) Drugs Sales, Revenue and Growth Rate Forecast (2018-2025)
        • 15.2.6 Taiwan Opioid Induced Constipation (OIC) Drugs Sales, Revenue and Growth Rate Forecast (2018-2025)
        • 15.2.7 India Opioid Induced Constipation (OIC) Drugs Sales, Revenue and Growth Rate Forecast (2018-2025)
        • 15.2.8 Southeast Asia Opioid Induced Constipation (OIC) Drugs Sales, Revenue and Growth Rate Forecast (2018-2025)
        • 15.2.9 Australia Opioid Induced Constipation (OIC) Drugs Sales, Revenue and Growth Rate Forecast (2018-2025)
      • 15.3 Asia-Pacific Opioid Induced Constipation (OIC) Drugs Sales, Revenue and Price Forecast by Type (2018-2025)
        • 15.3.1 Asia-Pacific Opioid Induced Constipation (OIC) Drugs Sales Forecast by Type (2018-2025)
        • 15.3.2 Asia-Pacific Opioid Induced Constipation (OIC) Drugs Revenue Forecast by Type (2018-2025)
        • 15.3.3 Asia-Pacific Opioid Induced Constipation (OIC) Drugs Price Forecast by Type (2018-2025)
      • 15.4 Asia-Pacific Opioid Induced Constipation (OIC) Drugs Sales Forecast by Application (2018-2025)

      16 Research Findings and Conclusion

        17 Appendix

        • 17.1 Methodology/Research Approach
          • 17.1.1 Research Programs/Design
          • 17.1.2 Market Size Estimation
          • 17.1.3 Market Breakdown and Data Triangulation
        • 17.2 Data Source
          • 17.2.1 Secondary Sources
          • 17.2.2 Primary Sources

        REPORT YOU MIGHT BE INTERESTED

        Purchase this Report

        $4,000.00
        $8,000.00
        3,168.00
        6,336.00
        3,696.00
        7,392.00
        605,160.00
        1,210,320.00
        333,480.00
        666,960.00
        Credit card Logo

        Related Reports


        Reason to Buy

        Request for Sample of this report